Evidence map›Paper›PMID 35173816›Full record

ArticleTherapeutic advances in medical oncology2021

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.

Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, Maddalena Barba, Teresa Gamucci, Maria Mauri, Enzo Maria Veltri, Icro Meattini, Rossana Berardi, Francesca Sofia Di Lisa and 70 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Observational
  3. Observational
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

80 authors at 20 institutions in 1 country.

Laura PizzutiDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Eriseld KrasniqiDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144 Rome, Italy.
Isabella SperdutiBiostatistics Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Maddalena BarbaDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144 Rome, Italy.
Teresa GamucciMedical Oncology, Sandro Pertini Hospital, Rome, Italy.
Maria MauriDivision of Oncology, San Giovanni Hospital, Rome, Italy.
Enzo Maria VeltriMedical Oncology Unit, Santa Maria Goretti, Latina, Italy.
Icro MeattiniRadiation Oncology Unit and Department of Clinical and Experimental Biomedical Sciences 'Mario Serio', Careggi University Hospital, University of Florence, Florence, Italy.
Rossana BerardiOncology Clinic, 'Ospedali iuniti di Ancona' Hospital, Ancona, Italy.
Francesca Sofia Di LisaDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Clara NatoliDepartment of Medical, Oral and Biotechnological Sciences and Center for Advanced Studies and Technology (CAST), G. D'Annunzio University, Chieti, Italy.
Mirco PistelliOncology Clinic, 'Ospedali Riuniti di Ancona' Hospital, Ancona, Italy.
Laura IezziOncology Division, Hospital 'Maria SS. dello Splendore' ASL 4, Giulianova, Italy.
Emanuela RisiSandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy.ORCID https://orcid.org/0000-0002-9307-9760
Nicola D'OstilioMedical Oncology Unit, Lanciano-Vasto, Italy.
Silverio TomaoMedical Oncology A, Policlinico Umberto I, Rome, Italy.
Corrado FicorellaMedical Oncology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Katia CannitaMedical Oncology, Mazzini Hospital, Teramo, Italy.
Ferdinando RiccardiOncology Unit, Antonio Cardarelli Hospital, Naples, Italy.
Alessandra CassanoU.O.C. Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Emilio BriaU.O.C. Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Maria Agnese FabbriMedical Oncology Unit, Belcolle Hospital, Viterbo, Italy.
Marco MazzottaMedical Oncology Unit, Belcolle Hospital, Viterbo, Italy.
Giacomo BarchiesiMedical Oncology A, Policlinico Umberto I, Rome, Italy.
Andrea BotticelliMedical Oncology B, Policlinico Umberto I, Rome, Italy.
Giuliana D'AuriaMedical Oncology, Sandro Pertini Hospital, Rome, Italy.
Anna CeribelliMedical Oncology Unit, San Camillo de Lellis Hospital, ASL Rieti, Rieti, Italy.
Andrea MichelottiUO Medical Oncology I, S. Chiara Hospital, Pisa, Italy.
Antonio RussoMedical Oncology, AOU Policlinico Paolo Giaccone, Palermo, Italy.ORCID https://orcid.org/0000-0002-4370-2008
Beatrice Taurelli SalimbeniMedical Oncology, Sapienza University, Policlinico S. Andrea, Rome, Italy.
Giuseppina SarobbaDepartment of Medical Oncology, ASL Nuoro, Nuoro, Italy.
Francesco GiottaDepartment of Medical Oncology, IRCCS Giovanni Paolo II Institute, Bari, Italy.
Ida ParisGynaecology - Oncology Unit, IRCCS Catholic University of the Sacred Heart, Rome, Italy.
Rosa SaltarelliUOC Oncology, San Giovanni Evangelista Hospital, ASL RM5, Rome, Italy.
Daniele MarinelliMedical Oncology B, Policlinico Umberto I, Rome, Italy.
Domenico CorsiMedical Oncology Unit, Fatebenefratelli Hospital, Rome, Italy.
Elisabetta Maria CapomollaDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Valentina SiniOncologia Medica, Ospedale Santo Spirito, Rome, Italy.
Luca MoscettiDivision of Medical Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Lucia MentucciaMedical Oncology, Ospedale 'Parodi-Delfino', Colleferro, Italy.
Giuseppe ToniniDepartment of Oncology, University Campus Biomedico of Rome, Rome, Italy.
Mimma RaffaeleUOSD Presidio Oncologico Cassia - S. Andrea, ASL Roma 1, Rome, Italy.
Luca MarchettiUOC Oncology, San Pietro Fatebenefratelli Hospital, Rome, Italy.
Mauro MinelliDivision of Oncology, San Giovanni Hospital, Rome, Italy.
Enzo Maria RuggeriMedical Oncology Unit, Belcolle Hospital, Viterbo, Italy.
Paola ScavinaSan Giovanni Addolorata Hospital, 00184 Rome, Italy.
Olivia BacciuDivision of Oncology, San Giovanni Hospital, Rome, Italy.
Nello SalesiMedical Oncology Unit, Santa Maria Goretti, Latina, Italy.
Lorenzo LiviRadiation Oncology Unit and Department of Clinical and Experimental Biomedical Sciences 'Mario Serio', Careggi University Hospital, University of Florence, Florence, Italy.
Nicola TinariDepartment of Medical, Oral and Biotechnological Sciences and Center for Advanced Studies and Technology (CAST), G. D'Annunzio University, Chieti, Italy.
Antonino GrassadoniaDepartment of Medical, Oral and Biotrechnological Sciences and Centre for Advanced Studues and Echnology (CAST), G. D'Annunzio University, Chieti, Italy.
Angelo Fedele ScintoMedical Oncology Unit, Fatebenefratelli Hospital, Rome, Italy.
Rosalinda RossiDivision of Oncology, San Giovanni Hospital, Rome, Italy.
Maria Rosaria ValerioMedical Oncology, AOU Policlinico Paolo Giaccone, Palermo, Italy.
Elisabetta LanducciUO Medical Oncology I, S. Chiara Hospital, Pisa, Italy.
Simonetta StaniOncologia Medica, Ospedale Santo Spirito, Rome, Italy.
Beatrice FratiniUO Medical Oncology I, S. Chiara Hospital, Pisa, Italy.
Marcello Maugeri-SaccàDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Michele De TursiDepartment of Medical, Oral and Biotechnological Sciences and Center for Advanced Studies and Technology (CAST), G. D'Annunzio University, Chieti, Italy.
Angela MaioneOncology Unit, Antonio Cardarelli Hospital, Naples, Italy.
Daniele SantiniDepartment of Oncology, University Campus Biomedico of Rome, Rome, Italy.
Armando OrlandiU.O.C. Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Vito LorussoDepartment of Medical Oncology, IRCCS Giovanni Paolo II Institute, Bari, Italy.
Enrico CortesiMedical Oncology B, Policlinico Umberto I, Rome, Italy.
Giuseppe SanguinetiDepartment of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Paola PinnaròDepartment of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Federico CappuzzoDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Lorenza LandiDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Claudio BottiDepartment of Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Federica TomaoDepartment of Gynecologic Oncology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
Sonia CappelliDepartment of Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Giulia BonCellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Fabio PelleDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Flavia CavicchiDepartment of Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Elena FiorioU.O.C. Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Jennifer FogliettaMedical Oncology, P.O. Narni-Amelia, Terni, Italy.
Simone ScagnoliDepartment of Medical and Surgical Sciences and Translational Medicine, Sapienza University of Rome, Rome, Italy.
Paolo MarchettiMedical Oncology B, Policlinico Umberto I, Rome, Italy.
Gennaro CilibertoScientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Patrizia ViciDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITPoliclinico Umberto I · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Chieti-Pescara · ITFatebenefratelli Hospital · ITOspedale di Belcolle · ITOspedale Santa Chiara · ITAzienda Ospedaliera San Giovanni Addolorata · ITAzienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo · ITEuropean Society for Sexual Medicine · ITIstituto Tumori Bari · ITOspedale Antonio Cardarelli · ITOspedale di Santo Spirito · ITOspedale Santa Maria Goretti · ITOspedali Riuniti di Ancona · ITUniversità Campus Bio-Medico · ITASL Roma · ITAssociazione Istituzione Libera Università Nuorese · ITBassano Bresciano Astronomical Observatory · ITCTO Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this issue and to provide a picture of the advancement of anti-HER2 treatments, we performed a large, multicenter, retrospective study of HER2-positive BC patients.

methodsThe observational PANHER study included 1,328 HER2-positive advanced BC patients treated with HER2 blocking agents since June 2000 throughout July 2020. Endpoints of efficacy were progression-free survival (PFS) and overall survival (OS).

resultsPatients who received a first-line pertuzumab-based regimen showed better PFS (

conclusionOur results confirmed a relevant impact of first-line pertuzumab-based treatment and showed lower efficacy of second-line T-DM1 in trastuzumab/pertuzumab pretreated, as compared with pertuzumab-naïve patients. Our findings may help delineate a more appropriate therapeutic strategy in HER2-positive metastatic BC. Prospective randomized trials addressing this topic are awaited.

Indexed as

advanced breast cancerHER2-positivelapatinibpertuzumabsequenceT-DM1

Identifiers

PMID35173816
PMCPMC8842182
OpenAlexW3217507393

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.